Discovery of novel dengue virus NS5 methyltransferase non-nucleoside inhibitors by fragment-based drug design

European Journal of Medicinal Chemistry

Volumn 125, Issue , 2017, Pages 865-880

  Benmansour, Fatiha ^a,b,c   Trist, Iuni ^d   Coutard, Bruno ^a,b   Decroly, Etienne ^a,b   Querat, Gilles ^e   Brancale, Andrea ^d   Barral, Karine ^a,b,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b CNRS   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e Aix Marseille University IRD 190 Inserm 1207   (France)

Author keywords

Antiviral activity; Dengue virus; Fragment linking strategy; N Phenyl (phenylcarbamoyl)amino benzene 1 sulfonamide derivatives; NS5 methyltransferase inhibitors; Phenyl (phenylcarbamoyl)amino benzene 1 sulfonate derivatives

Indexed keywords

4 [3 [[(2 AMINO 4 CHLOROPHENYL)CARBAMOYL]AMINO]BENZENESULFONAMIDO]BENZOIC ACID; 4 [3 [[[2 AMINO 4 (TRIFLUOROMETHYL)PHENYL]CARBAMOYL]AMINO]BENZENESULFONAMIDO]BENZOIC ACID; 4 [4 [[(2 AMINO 4 CHLOROPHENYL)CARBAMOYL]AMINO]BENZENESULFONAMIDO]BENZOIC ACID; 4 [4 [[[2 AMINO 4 (TRIFLUOROMETHYL)PHENYL]CARBAMOYL]AMINO]BENZENESULFONAMIDO]BENZOIC ACID; 4 [[(4 CHLORO 2 NITROPHENYL)CARBAMOYL]AMINO]BENZENE 1 SULFONIC ACID; 4 [[(4 CHLORO 2 NITROPHENYL)CARBAMOYL]AMINO]BENZENE 1 SULFONYLCHLORIDE; 4 [[3 [[(2 AMINO 4 CHLOROPHENYL)CARBAMOYL]AMINO]BENZENESULFONYL]OXY]BENZOIC ACID; 4 [[4 [[(2 AMINO 4 CHLOROPHENYL)CARBAMOYL]AMINO]BENZENESULFONYL]OXY]BENZOIC ACID; 4 [[[2 NITRO 4 (TRIFLUOROMETHYL)PHENYL]CARBAMOYL]AMINO]BENZENE 1 SULFONIC ACID; 4 [[[2 NITRO 4 (TRIFLUOROMETHYL)PHENYL]CARBAMOYL]AMINO]BENZENE 1 SULFONYLCHLORIDE; ANTIVIRUS AGENT; METHYL 4 [4 [[(4 CHLORO 2 NITROPHENYL)CARBAMOYL]AMINO]BENZENESULFONAMIDO]BENZOATE; METHYL 4 [4 [[[2 NITRO 4 (TRIFLUOROMETHYL)PHENYL]CARBAMOYL]AMINO]BENZENESULFONAMIDO]BENZOATE; METHYL 4 [[4 [[(4 CHLORO 2 NITROPHENYL)CARBAMOYL]AMINO]BENZENESULFONYL]OXY]BENZOATE; METHYLTRANSFERASE INHIBITOR; NONSTRUCTURAL PROTEIN 5; UNCLASSIFIED DRUG; UREA DERIVATIVE; ENZYME INHIBITOR; LIGAND; METHYLTRANSFERASE; NS5 PROTEIN, DENGUE VIRUS; SULFATE; SULFONAMIDE; VIRAL PROTEIN;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CRYSTAL STRUCTURE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; IC50; LIQUID CHROMATOGRAPHY; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; PROTON NUCLEAR MAGNETIC RESONANCE; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DENGUE VIRUS; DRUG DEVELOPMENT; ENZYMOLOGY; HUMAN;

ANTIVIRAL AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DENGUE VIRUS; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; LIGANDS; METHYLTRANSFERASES; SULFATES; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84991677473     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.10.007     Document Type: Article

References (65)

1. [1] Thomas, S.J., Endy, T.P., Current issues in dengue vaccination. Curr. Opin. Infect. Dis. 26 (2013), 429–434.
2. [2] Bollati, M., Alvarez, K., Assenberg, R., Baronti, C., Canard, B., Cook, S., Coutard, B., Decroly, E., de Lamballerie, X., Gould, E.A., Grard, G., Grimes, J.M., Hilgenfeld, R., Jansson, A.M., Malet, H., Mancini, E.J., Mastrangelo, E., Mattevi, A., Milani, M., Moureau, G., Neyts, J., Owens, R.J., Ren, J., Selisko, B., Speroni, S., Steuber, H., Stuart, D.I., Unge, T., Bolognesi, M., Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antivir. Res. 87 (2010), 125–148.
3. [3] Bhakat, S., Karubiu, W., Jayaprakash, V., Soliman, M.E.S., A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses. Eur. J. Med. Chem. 87 (2014), 677–702.
4. [4] Lim, S.P., Noble, C.G., Shi, P.Y., The dengue virus NS5 protein as a target for drug discovery. Antivir. Res. 119 (2015), 57–67.
5. [5] Dong, H.P., Chang, D.C., Xie, X.P., Toh, Y.X., Chung, K.Y., Zou, G., Lescar, J., Lim, S.P., Shi, P.Y., Biochemical and genetic characterization of dengue virus methyltransferase. Virology 405 (2010), 568–578.
6. [6] Dong, H.P., Zhang, B., Shi, P.Y., Flavivirus methyltransferase: a novel antiviral target. Antivir. Res. 80 (2008), 1–10.
7. [7] Zust, R., Cervantes-Barragan, L., Habjan, M., Maier, R., Neuman, B.W., Ziebuhr, J., Szretter, K.J., Baker, S.C., Barchet, W., Diamond, M.S., Siddell, S.G., Ludewig, B., Thiel, V., Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 12 (2011), 137–143.
8. [8] Zust, R., Dong, H., Li, X.F., Chang, D.C., Zhang, B., Balakrishnan, T., Toh, Y.X., Jiang, T., Li, S.H., Deng, Y.Q., Ellis, B.R., Ellis, E.M., Poidinger, M., Zolezzi, F., Qin, C.F., Shi, P.Y., Fink, K., Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques. PLoS Pathog., 9, 2013, e1003521.
9. [9] Lim, S.P., Sonntag, L.S., Noble, C., Nilar, S.H., Ng, R.H., Zou, G., Monaghan, P., Chung, K.Y., Dong, H.P., Liu, B.P., Bodenreider, C., Lee, G., Ding, M., Chan, W.L., Wang, G., Jian, Y.L., Chao, A.T., Lescar, J., Yin, Z., Vedananda, T.R., Keller, T.H., Shi, P.Y., Small molecule inhibitors that selectively block dengue virus methyltransferase. J. Biol. Chem. 286 (2011), 6233–6240.
10. [10] Lim, S.P., Wang, Q.Y., Noble, C.G., Chen, Y.L., Dong, H., Zou, B., Yokokawa, F., Nilar, S., Smith, P., Beer, D., Lescar, J., Shi, P.Y., Ten years of dengue drug discovery: progress and prospects. Antivir. Res. 100 (2013), 500–519.
11. [11] Murray, C.W., Rees, D.C., The rise of fragment-based drug discovery. Nat. Chem. 1 (2009), 187–192.
12. [12] Congreve, M., Chessari, G., Tisi, D., Woodhead, A.J., Recent developments in fragment-based drug discovery. J. Med. Chem. 51 (2008), 3661–3680.
13. [13] de Kloe, G.E., Bailey, D., Leurs, R., de Esch, I.J., Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discov. Today 14 (2009), 630–646.
14. [14] Erlanson, D.A., Introduction to fragment-based drug discovery. Top. Curr. Chem. 317 (2012), 1–32.
15. [15] Hajduk, P.J., Greer, J., A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6 (2007), 211–219.
16. [16] Scott, D.E., Coyne, A.G., Hudson, S.A., Abell, C., Fragment-based approaches in drug discovery and chemical biology. Biochemistry 51 (2012), 4990–5003.
17. [17] Coutard, B., Decroly, E., Li, C.Q., Sharff, A., Lescar, J., Bricogne, G., Barral, K., Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery. Antivir. Res. 106 (2014), 61–70.
18. [18] Borsi, V., Calderone, V., Fragai, M., Luchinat, C., Sarti, N., Entropic contribution to the linking coefficient in fragment based drug design: a case study. J. Med. Chem. 53 (2010), 4285–4289.
19. [19] Shuker, S.B., Hajduk, P.J., Meadows, R.P., Fesik, S.W., Discovering high-affinity ligands for proteins: SAR by NMR. Science 274 (1996), 1531–1534.
20. [20] McInnis, C.E., Blackwell, H.E., Design, synthesis, and biological evaluation of abiotic, non-lactone modulators of LuxR-type quorum sensing. Bioorgan. Med. Chem. 19 (2011), 4812–4819.
21. [21] Wood, D.M., Greenland, B.W., Acton, A.L., Rodriguez-Llansola, F., Murray, C.A., Cardin, C.J., Miravet, J.F., Escuder, B., Hamley, I.W., Hayes, W., pH-tunable hydrogelators for water purification: structural optimisation and evaluation. Chem.-A Eur. J. 18 (2012), 2692–2699.
22. [22] Anderson, M.O., Yu, H., Penaranda, C., Maddux, B.A., Goldfine, I.D., Youngren, J.F., Guy, R.K., Parallel synthesis of diarylureas and their evaluation as inhibitors of insulin-like growth factor receptor. J. Comb. Chem. 8 (2006), 784–790.
23. [23] Oguro, Y., Miyamoto, N., Okada, K., Takagi, T., Iwata, H., Awazu, Y., Miki, H., Hori, A., Kamiyama, K., Imamura, S., Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorgan. Med. Chem. 18 (2010), 7260–7273.
24. [24] Zhang, Y.Q., Anderson, M., Weisman, J.L., Lu, M., Choy, C.J., Boyd, V.A., Price, J., Sigal, M., Clark, J., Connelly, M., Zhu, F.Y., Guiguemde, W.A., Jeffries, C., Yang, L., Lemoff, A., Liou, A.P., Webb, T.R., DeRisi, J.L., Guy, R.K., Evaluation of diarylureas for activity against Plasmodium falciparum. Acs Med. Chem. Lett. 1 (2010), 460–465.
25. [25] Kubo, K., Shimizu, T., Ohyama, S., Murooka, H., Iwai, A., Nakamura, K., Hasegawa, K., Kobayashi, Y., Takahashi, N., Takahashi, K., Kato, S., Izawa, T., Isoe, T., Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N '-{4-[4-quinolyloxy)phenyl}ureas. J. Med. Chem. 48 (2005), 1359–1366.
26. [26] Usharani, V., Rao, A.K.S.B., Reddy, M.P., Dubey, P.K., Synthesis of aryl urea derivatives from aryl amines and aryl isocyanates. Asian J. Chem. 23 (2011), 1802–1806.
27. [27] Cao, G.R., Zhao, X.Y., Xiao, R.J., Study on synthesis of nitrophenyl isocyanates using triphosgene. Adv. Mater Res. -Switz. 550–553 (2012), 1039–1042.
28. [28] Yu, B., Tang, L.D., Li, Y.L., Song, S.H., Ji, X.L., Lin, M.S., Wu, C.F., Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase. Bioorg. Med. Chem. Lett. 22 (2012), 110–114.
29. [29] Liu, D.Z., Tian, Z., Yan, Z.H., Wu, L.X., Ma, Y., Wang, Q., Liu, W., Zhou, H.G., Yang, C., Design, synthesis and evaluation of 1,2-benzisothiazol-3-one derivatives as potent caspase-3 inhibitors. Bioorgan. Med. Chem. 21 (2013), 2960–2967.
30. [30] J.R. Rusche, N.P. Peet, A.T. Hopper, Compositions Including 6-aminohexanoic Acid Derivatives as HDAC Inhibitors, PCT WO 2010/028192, (11.03.201).
31. [31] Valgeirsson, J., Nielsen, E.O., Peters, D., Mathiesen, C., Kristensen, A.S., Madsen, U., Bioisosteric modifications of 2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. J. Med. Chem. 47 (2004), 6948–6957.
32. [32] Jose, D.A., Kumar, D.K., Kar, P., Verma, S., Ghosh, A., Ganguly, B., Ghosh, H.N., Das, A., Role of positional isomers on receptor-anion binding and evidence for resonance energy transfer. Tetrahedron 63 (2007), 12007–12014.
33. [33] Klinkhammer, W., Muller, H., Globisch, C., Pajeva, I.K., Wiese, M., Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators. Bioorgan. Med. Chem. 17 (2009), 2524–2535.
34. [34] Li, Z.G., Huang, H., Sun, H.B., Hang, H.L., Liu, H., Microwave-assisted efficient and convenient synthesis of 2,4(1H,3H)-quinazolinediones and 2-thioxoquinazolines. J. Comb. Chem. 10 (2008), 484–486.
35. [35] Egloff, M.P., Benarroch, D., Selisko, B., Romette, J.L., Canard, B., An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J. 21 (2002), 2757–2768.
36. [36] Benarroch, D., Egloff, M.P., Mulard, L., Guerreiro, C., Romette, J.L., Canard, B., A structural basis for the inhibition of the NS5 dengue virus mRNA 2'-O-methyltransferase domain by ribavirin 5'-triphosphate. J. Biol. Chem. 279 (2004), 35638–35643.
37. [37] Egloff, M.P., Decroly, E., Malet, H., Selisko, B., Benarroch, D., Ferron, F., Canard, B., Structural and functional analysis of methylation and 5'-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5. J. Mol. Biol. 372 (2007), 723–736.
38. [38] Yap, L.J., Luo, D., Chung, K.Y., Lim, S.P., Bodenreider, C., Noble, C., Shi, P.Y., Lescar, J., Crystal structure of the dengue virus methyltransferase bound to a 5'-capped octameric RNA. PLoS One, 5, 2010.
39. [39] Geiss, B.J., Thompson, A.A., Andrews, A.J., Sons, R.L., Gari, H.H., Keenan, S.M., Peersen, O.B., Analysis of flavivirus NS5 methyltransferase cap binding. J. Mol. Biol. 385 (2009), 1643–1654.
40. [40] Lum, R.T., Cheng, M., Cristobal, C.P., Goldfine, I.D., Evans, J.L., Keck, J.G., Macsata, R.W., Manchem, V.P., Matsumoto, Y., Park, S.J., Rao, S.S., Robinson, L., Shi, S., Spevak, W.R., Schow, S.R., Design, synthesis, and structure-activity relationships of novel insulin receptor tyrosine kinase activators. J. Med. Chem. 51 (2008), 6173–6187.
41. [41] Ganesh, T., Thepchatri, P., Li, L., Du, Y.H., Fu, H.A., Snyder, J.P., Sun, A.M., Synthesis and SAR study of N-(4-hydroxy-3-(2-hydroxynaphthalene-1yl)phenyl)arylsulfonamides: heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in vitro assay. Bioorg. Med. Chem. Lett. 18 (2008), 4982–4987.
42. [42] Barral, K., Sallamand, C., Petzold, C., Coutard, B., Collet, A., Thillier, Y., Zimmermann, J., Vasseur, J.J., Canard, B., Rohayem, J., Debart, F., Decroly, E., Development of specific dengue virus 2'-O- and N7-methyltransferase assays for antiviral drug screening. Antivir. Res. 99 (2013), 292–300.
43. [43] Abad-Zapatero, C., Ligand efficiency indices for effective drug discovery. Expert Opin. Drug Discov. 2 (2007), 469–488.
44. [44] Zhao, Y., Soh, T.S., Lim, S.P., Chung, K.Y., Swaminathan, K., Vasudevan, S.G., Shi, P.Y., Lescar, J., Luo, D., Molecular basis for specific viral RNA recognition and 2'-O-ribose methylation by the dengue virus nonstructural protein 5 (NS5). Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 14834–14839.
45. [45] Benmansour, F., Eydoux, C., Querat, G., de Lamballerie, X., Canard, B., Alvarez, K., Guillemot, J.C., Barral, K., Novel 2-phenyl-5-[(E)-2-(thiophen-2-yl)ethenyl]-1,3,4-oxadiazole and 3-phenyl-5-[(E)-2-(thiophen-2-yl)ethenyl]-1,2,4-oxadiazole derivatives as dengue virus inhibitors targeting NS5 polymerase. Eur. J. Med. Chem. 109 (2016), 146–156.
46. [46] Chemical Computing Group Inc. Molecular Operating Environment (MOE) 2010.10, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7 (2010).
47. [47] Chemical Computing Group Inc., Molecular Operating Environment (MOE) 2011.10, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7 (2011).
48. [48] Van der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A.E., Berendsen, H.J.C., GROMACS: fast, flexible, and free. J. Comput. Chem. 26 (2005), 1701–1718.
49. [49] Case, D.A., Darden, T.A., Cheatham, T.E., Simmerling, C.L., Wang, J., Duke, R.E., Luo, R., Walker, R.C., Zhang, W., Merz, K.M., Roberts, B., Hayik, S., Roitberg, A., Seabra, G., Swails, J., Gôtz, A.W., Kolossvàry, I., Wong, K.F., Paesani, F., Vanicek, J., Wolf, R.M., Liu, J., Wu, X., Brozell, S.R., Steinbrecher, T., Gohlke, H., Cai, Q., Ye, X., Wang, J., Hsieh, M.-J., Cui, G., Roe, D.R., Mathwes, D.H., Seetin, M.G., Salomon-Ferrer, R., Sagui, C., Babin, V., Luchko, T., Gustarov, S., Kovalenko, A., Kollman, P.A., AMBER 12. 2012, University of California.
50. [50] Sousa da Silva, A.W., Vranken, W.F., ACPYPE - AnteChamber PYthon Parser interface. BMC Res. Notes 5, 367, 2012, 10.1186/1756-0500-5-367.
51. [51] Humphrey, W., Dalke, A., Schulten, K., VMD: visual molecular dynamics. J. Mol. Graph. Model. 14 (1996), 33–38.
52. [52] Stambulchik, E., Grace. 1998-2000 retrieved 2009-06-20.
53. [53] Suite, 2012: Maestro, Version 9.3. 2012, Schrödinger, LLC, New York, NY.
54. [54] Sharff, A., Keller, P., Vonrhein, C., Smart, O., Womack, T., Flensburg, C., Paciorek, C., Bricogne, G., Pipedream, Version 0.1.4. 2011, Global Phasing Ltd, Cambridge, United Kingdom.
55. [55] Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O., Paciorek, W., Womack, T., Bricogne, G., Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D. Biol. Crystallogr. 67 (2011), 293–303.
56. [56] McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., Read, R.J., Phaser crystallographic software. J. Appl. Crystallogr. 40 (2007), 658–674.
57. [57] Bricogne, G., Blanc, E., Brandl, M., Flensburg, C., Keller, P., Paciorek, W., Roversi, P., Sharff, A., Smart, O.S., Vonrhein, C., Womack, T.O., BUSTER Version 2.11.2. 2011, Global Phasing Ltd, Cambridge, United Kingdom.
58. [58] Womack, T., Smart, O., Sharff, A., Flensburg, C., Keller, P., Paciorek, W., Vonrhein, C., Bricogne, G., Rhofit, Version 1.2.3. 2011, Global Phasing Ltd, Cambridge, United Kingdom.
59. [59] Kabsch, W., Xds. Acta Crystallogr. D. Biol. Crystallogr. 66 (2010), 125–132.
60. [60] Evans, P., Scaling and assessment of data quality. Acta Crystallogr. D. Biol. Crystallogr. 62 (2006), 72–82.
61. [61] Emsley, P., Lohkamp, B., Scott, W.G., Cowtan, K., Features and development of coot. Acta Crystallogr. D. Biol. Crystallogr. 66 (2010), 486–501.
62. [62] Davis, I.W., Leaver-Fay, A., Chen, V.B., Block, J.N., Kapral, G.J., Wang, X., Murray, L.W., Arendall, W.B. 3rd, Snoeyink, J., Richardson, J.S., Richardson, D.C., MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35 (2007), W375–W383.
63. [63] Milani, M., Mastrangelo, E., Bollati, M., Selisko, B., Decroly, E., Bouvet, M., Canard, B., Bolognesi, M., Flaviviral methyltransferase/RNA interaction: structural basis for enzyme inhibition. Antivir. Res. 83 (2009), 28–34.
64. [64] Selisko, B., Peyrane, F.F., Canard, B., Alvarez, K., Decroly, E., Biochemical characterization of the (nucleoside-2'O)-methyltransferase activity of dengue virus protein NS5 using purified capped RNA oligonucleotides (7Me)GpppAC(n) and GpppAC(n). J. Gen. Virol. 91 (2010), 112–121.
65. [65] Delean, A., Munson, P.J., Rodbard, D., Simultaneous analysis of families of sigmoidal curves - application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235 (1978), E97–E102.